ATARA BIOTHERAPEUTICS INC (ATRA)
US0465132068 - Common Stock
ATRA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. ATRA may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, ATRA is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
ATRA had negative earnings in the past year.
In the past year ATRA has reported a negative cash flow from operations.
ATRA had negative earnings in each of the past 5 years.
In the past 5 years ATRA always reported negative operating cash flow.
1.2 Ratios
ATRA has a Return On Assets of -93.31%. This is in the lower half of the industry: ATRA underperforms 73.63% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -93.31% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-100.05%
ROA(5y)-87.43%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 82.70%, ATRA belongs to the top of the industry, outperforming 87.43% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for ATRA so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 82.7% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ATRA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ATRA has less shares outstanding
Compared to 5 years ago, ATRA has less shares outstanding
ATRA has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -22.45, we must say that ATRA is in the distress zone and has some risk of bankruptcy.
ATRA has a Altman-Z score of -22.45. This is amonst the worse of the industry: ATRA underperforms 87.43% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -22.45 |
ROIC/WACCN/A
WACC9.93%
2.3 Liquidity
A Current Ratio of 0.59 indicates that ATRA may have some problems paying its short term obligations.
The Current ratio of ATRA (0.59) is worse than 93.10% of its industry peers.
ATRA has a Quick Ratio of 0.59. This is a bad value and indicates that ATRA is not financially healthy enough and could expect problems in meeting its short term obligations.
ATRA has a worse Quick ratio (0.50) than 93.27% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.59 | ||
| Quick Ratio | 0.5 |
3. Growth
3.1 Past
ATRA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 62.91%, which is quite impressive.
Looking at the last year, ATRA shows a very strong growth in Revenue. The Revenue has grown by 2107.45%.
EPS 1Y (TTM)62.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%82.24%
Revenue 1Y (TTM)2107.45%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%1779.79%
3.2 Future
ATRA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.19% yearly.
The Revenue is expected to grow by 51.82% on average over the next years. This is a very strong growth
EPS Next Y87%
EPS Next 2Y38.45%
EPS Next 3Y24.25%
EPS Next 5Y14.19%
Revenue Next Year684.54%
Revenue Next 2Y160.03%
Revenue Next 3Y66.56%
Revenue Next 5Y51.82%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ATRA. In the last year negative earnings were reported.
Also next year ATRA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as ATRA's earnings are expected to grow with 24.25% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.45%
EPS Next 3Y24.25%
5. Dividend
5.1 Amount
No dividends for ATRA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ATARA BIOTHERAPEUTICS INC
NASDAQ:ATRA (1/14/2025, 8:24:35 PM)
Premarket: 13.29 +0.98 (+7.96%)12.31
-3.88 (-23.97%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners51.09%
Inst Owner Change0%
Ins Owners2.05%
Ins Owner Change0.39%
Market Cap70.91M
Analysts78.46
Price Target16.66 (35.34%)
Short Float %11.94%
Short Ratio4.39
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-71.58%
Min EPS beat(2)-94.51%
Max EPS beat(2)-48.64%
EPS beat(4)1
Avg EPS beat(4)-36.26%
Min EPS beat(4)-94.51%
Max EPS beat(4)12.03%
EPS beat(8)3
Avg EPS beat(8)-32.65%
EPS beat(12)5
Avg EPS beat(12)-18.39%
EPS beat(16)7
Avg EPS beat(16)-14.48%
Revenue beat(2)1
Avg Revenue beat(2)-8.87%
Min Revenue beat(2)-29.79%
Max Revenue beat(2)12.04%
Revenue beat(4)2
Avg Revenue beat(4)-18.26%
Min Revenue beat(4)-63.91%
Max Revenue beat(4)12.04%
Revenue beat(8)2
Avg Revenue beat(8)-49.95%
Revenue beat(12)4
Avg Revenue beat(12)15.82%
Revenue beat(16)6
Avg Revenue beat(16)15.05%
PT rev (1m)10.73%
PT rev (3m)-81.95%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1577.93%
EPS NY rev (1m)0%
EPS NY rev (3m)-10.75%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)7.8%
Revenue NY rev (1m)-1.97%
Revenue NY rev (3m)11.55%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.71 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-25.78
EYN/A
EPS(NY)-5.45
Fwd EYN/A
FCF(TTM)-16.47
FCFYN/A
OCF(TTM)-16.43
OCFYN/A
SpS17.44
BVpS-15.72
TBVpS-15.72
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -93.31% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 82.7% | ||
| FCFM | N/A |
ROA(3y)-100.05%
ROA(5y)-87.43%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.7
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 3.86% | ||
| Cap/Sales | 0.2% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.59 | ||
| Quick Ratio | 0.5 | ||
| Altman-Z | -22.45 |
F-Score4
WACC9.93%
ROIC/WACCN/A
Cap/Depr(3y)70.88%
Cap/Depr(5y)69.57%
Cap/Sales(3y)24.29%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)62.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%82.24%
EPS Next Y87%
EPS Next 2Y38.45%
EPS Next 3Y24.25%
EPS Next 5Y14.19%
Revenue 1Y (TTM)2107.45%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%1779.79%
Revenue Next Year684.54%
Revenue Next 2Y160.03%
Revenue Next 3Y66.56%
Revenue Next 5Y51.82%
EBIT growth 1Y59.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year75.37%
EBIT Next 3Y9.82%
EBIT Next 5Y8.28%
FCF growth 1Y62.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y61.81%
OCF growth 3YN/A
OCF growth 5YN/A